Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 12 of 12« First...89101112

Independence of compliance reviews is questioned in drug firm settlements

Drug companies have hired auditors to perform compliance reviews mandated in government settlements over alleged civil violations.

Read More »

Abbott Tries to Bail Out of $5.8 Billion Deal as Alere Faces Bribery Probes, But it Won’t Be Easy

Abbott Laboratories sought a way out of its $5.8 billion deal to acquire Alere Inc. in the wake of a bribery probe into that company’s sales practices in Africa, Asia and Latin America, Bloomberg reported.

Read More »

Novartis’ New $1 Billion Shanghai Home

Novartis opened a new $1 billion research facility on the outskirts of Shanghai, China. The facility is the company’s third major research center.

Read More »

GSK seeks lead in triple lung drug market

GlaxoSmithKline is on track to file its three-in-one inhaled lung drug for U.S. approval by the end of 2016 rather than during first-half 2018 as initially planned.

Read More »

AstraZeneca sells EU, Latam gout drug rights to Gruenenthal

AstraZeneca has sold the European and Latin American rights to its new gout drug Zurampic to private German drugmaker Gruenenthal for up to $230 million, following a similar disposal of U.S. rights to the medicine.

Read More »

Novartis gets win with Afinitor in Europe

Efforts by Novartis to defend its blockbuster cancer drug Afinitor against competitors got a boost from European regulators, who approved it for use on certain types of advanced gastrointestinal and lung neuroendocrine tumors.

Read More »

Klick Health Announces New York Office, Hires More Top Talent

Company continues to expand and disrupt the industry as Agency of the Future   TORONTO, ON – June 1, 2016 – Start spreading the news – Klick Health today announced it is opening an office in New York as it continues to build one of the best talent rosters in the healthcare and pharma marketing […]

Read More »

FDA calls for sharp reduction in salt added to foods

U.S. health officials recommended cutting the amount of salt added to foods to help Americans reduce their sodium consumption by about a third.

Read More »

Ionis Pharma’s Pain Propels Alnylam to Gain $1.5 Billion in Market Cap

One company’s loss is another company’s gain. That’s certainly the case when looking at California-based Ionis Pharmaceuticals and Massachusetts-based Alnylam.

Read More »

StemCells to Cease Operations

StemCells Inc. announced it will “wind down operations” following disappointing results of a Phase II spinal cord injury therapy study.

Read More »

BioMarin Shutters Its Kyndrisa Duchenne Program

San Rafael, California-based BioMarin Pharmaceutical announced that it is abandoning its Kyndrisa (drisapersen) program for Duchenne muscular dystrophy (DMD).

Read More »

Activist Investor Carl Icahn’s Big Buy of Allergan Shares Raises Questions of Influence

Activist investor Carl Icahn posted on his website that he had acquired a “large position” in Dublin-based Allergan Plc. This statement had many investors and analysts raising their eyebrows.

Read More »

Burden of pricey hepatitis C drugs heaviest in eastern Europe

New hepatitis C drugs that can cure the liver-destroying disease are revolutionizing treatment but their high price is a huge burden in some countries, particularly in central and eastern Europe, according to a new study.

Read More »

Page 12 of 12« First...89101112

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom